title: Prevalence of celiac disease and gluten sensitivity in the United States clinical antipsychotic trials of intervention effectiveness study population.
abstract: Celiac disease (CD) and schizophrenia have approximately the same prevalence, but epidemiologic data show higher prevalence of CD among schizophrenia patients. The reason for this higher co-occurrence is not known, but the clinical knowledge about the presence of immunologic markers for CD or gluten intolerance in schizophrenia patients may have implications for treatment. Our goal was to evaluate antibody prevalence to gliadin (AGA), transglutaminase (tTG), and endomysium (EMA) in a group of individuals with schizophrenia and a comparison group. AGA, tTG, and EMA antibodies were assayed in 1401 schizophrenia patients who were part of the Clinical Antipsychotic Trials of Intervention Effectiveness study and 900 controls. Psychopathology in schizophrenia patients was assessed using the Positive and Negative Symptoms Scale (PANSS). Logistic regression was used to assess the difference in the frequency of AGA, immunoglobulin A (IgA), and tTG antibodies, adjusting for age, sex, and race. Linear regression was used to predict PANSS scores from AGA and tTG antibodies adjusting for age, gender, and race. Among schizophrenia patients, 23.1% had moderate to high levels of IgA-AGA compared with 3.1% of the comparison group (χ(2) = 1885, df = 2, P < .001.) Moderate to high levels of tTG antibodies were present in 5.4% of schizophrenia patients vs 0.80% of the comparison group (χ(2) = 392.0, df = 2, P < .001). Adjustments for sex, age, and race had trivial effects on the differences. Regression analyses failed to predict PANSS scores from AGA and tTG antibodies. Persons with schizophrenia have higher than expected titers of antibodies related to CD and gluten sensitivity.
authors.affiliation: Department of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine, 600 North Wolfe Street, Meyer 144, Baltimore, MD 21287, USA. cascella@jhmi.edu
authors.forename: Nicola G
authors.initials: NG
authors.lastname: Cascella
authors.forename: Debra
authors.initials: D
authors.lastname: Kryszak
authors.forename: Bushra
authors.initials: B
authors.lastname: Bhatti
authors.forename: Patricia
authors.initials: P
authors.lastname: Gregory
authors.forename: Deanna L
authors.initials: DL
authors.lastname: Kelly
authors.forename: Joseph P
authors.initials: JP
authors.lastname: Mc Evoy
authors.forename: Alessio
authors.initials: A
authors.lastname: Fasano
authors.forename: William W
authors.initials: WW
authors.lastname: Eaton
mesh_terms: D000328:Adult; D000906:Antibodies / Q000097:blood; D014150:Antipsychotic Agents / Q000627:therapeutic use; D001323:Autoantibodies / Q000097:blood; D002446:Celiac Disease / Q000175:diagnosis / Q000453:epidemiology* / Q000276:immunology; D015897:Comorbidity; D005260:Female; D005903:Gliadin / Q000276:immunology; D005983:Glutens / Q000276:immunology*; D006801:Humans; D007070:Immunoglobulin A / Q000097:blood; D008297:Male; D008875:Middle Aged; D009132:Muscles / Q000276:immunology; D015995:Prevalence; D012559:Schizophrenia / Q000175:diagnosis / Q000188:drug therapy / Q000453:epidemiology*; D011503:Transglutaminases / Q000276:immunology; D016896:Treatment Outcome; D014481:United States / Q000453:epidemiology
chemical_list: D000906:Antibodies; D014150:Antipsychotic Agents; D001323:Autoantibodies; D007070:Immunoglobulin A; D005983:Glutens; D005903:Gliadin; D011503:Transglutaminases